Letter to the Editor

Stelios F. Assimakopoulos, Georgios K. Markantes, Dimitris Papageorgiou, Irene Mamali, Kostas B. Markou, Markos Marangos and Marina A. Michalaki*

Low serum TSH in the acute phase of COVID-19 pneumonia: thyrotoxicosis or a face of “non-thyroidal illness syndrome”?  

https://doi.org/10.1515/cclm-2021-0511
Received April 28, 2021; accepted May 31, 2021; published online July 12, 2021

Keywords: COVID-19; non-thyroidal illness; thyroid function; thyroid stimulating hormone (TSH); thyrotoxicosis.

To the Editor,

Since the emergence of the coronavirus disease (COVID-19) pandemic, several studies have examined the effects of SARS-CoV-2 infection on thyroid function [1–6]. Available evidence suggests that thyroid function tests (TFT) are altered during COVID-19, but the involved pathophysiological mechanisms have not been clarified. Some investigators have attributed the observed alterations to thyrotoxicosis [1, 2], while others consider them compatible with the “Non-Thyroidal Illness Syndrome” (NTIS) [3–6]. The term NTIS describes the alterations in TFT (namely decreased triiodothyronine-T3, low/normal thyroxine-T4 and thyrotropin-thyroid stimulating hormone (TSH) and increased reverse triiodothyronine-rT3) observed during illness or starvation in individuals without pre-existing thyroid disease and intact hypothalamus-pituitary-thyroid (HPT) axis. Our aim was to investigate the alterations in TFT in patients hospitalized for COVID-19 pneumonia within the first 24 h of admission and before the administration of any medication known to influence the HPT axis, and to examine if such alterations had prognostic significance.

We prospectively studied 22 consecutive patients hospitalized at the University Hospital of Patras from March 3 to May 10, 2020 diagnosed with COVID-19 pneumonia according to established criteria [7]. SARS-CoV-2 infection was confirmed by RT-PCR of nasopharyngeal swab samples. Pneumonia severity classification was based on the American Thoracic Society guidelines [8]. Patients were followed for 14 days for development of severe respiratory failure (SRF) (defined as PO2/FiO2 <200) requiring mechanical ventilation (MV). Nineteen age and sex-matched hospitalized patients with community-acquired non-COVID-19 pneumonia of the same severity and nineteen healthy persons were included as controls. None of the participants had a history of thyroid disease or was on drugs affecting thyroid function at enrolment. None of our COVID-19 patients received glucocorticoids, dopamine/dobutamine or iodinated contrasts before blood sampling for thyroid function tests. Prophylactic low-molecular-weight heparin (LMWH) was administered according to COVID-19 treatment guidelines [7], after blood sampling for TFT. The study was approved by the University Hospital of Patras Ethics Committee, while all participants provided informed consent. TSH, total and free thyroxine (T4 and FT4) and triiodothyronine (T3 and FT3), rT3, anti-thyroid peroxidase antibodies (Ab-TPO), CRP, ferritin and D-dimers were measured within 24 h of admission. Serum T3, FT3, T4, FT4, TSH and Ab-TPO were measured by electrochemiluminescence immunoassays (Cobas e601, Roche Diagnostics®, Germany), while rT3 was measured by competitive enzyme immunoassay (BioVendor®, Czech Republic).

Data were analyzed using SPSS 25.0 for Windows (SPSS Inc., Chicago, IL). Parameters were tested for
normality with the Shapiro–Wilk test. Comparisons between groups were performed using Student’s t-test or one-way ANOVA (normally distributed data) and Mann–Whitney U test or Kruskal–Wallis test (non-normally distributed data). Frequencies were compared with the chi-squared test. Correlations were estimated by Pearson or Spearman correlation tests. All tests were 2-tailed and a p-value of less than 0.05 was considered significant.

Inflammatory markers and D-Dimers were significantly higher in patients with COVID-19 and non-COVID-19 pneumonia compared to healthy controls but did not differ between COVID-19 and non-COVID-19 pneumonia (Table 1). T3, FT3 and TSH were lower, T4 similar, and FT4 and Ab-TPO higher in both patient groups compared to healthy controls. rT3 was slightly higher in COVID-19 patients than in healthy participants (Table 1). Seven COVID-19 patients (31.8%) had a constellation of low TSH (<0.5 mIU/L), low/low-normal T3 and FT3, normal T4 and FT4, and increased rT3 (Supplementary Table 1). This pattern was observed in only one patient without COVID-19 pneumonia. Ab-TPO levels were positively correlated with ferritin values in subjects with COVID-19 pneumonia (Spearman’s rho=0.531, p<0.05).

Higher proportion of males and higher levels of ferritin and/or CRP characterized the COVID-19 patients with severe pneumonia and need for MV. Patients in need for MV had higher Ab-TPO levels, while Ab-TPO positivity was significantly more common in the COVID-19 groups with severe pneumonia and need for MV (Table 2).

In most studies investigating thyroid function in COVID-19, including ours, TSH levels are decreased in severe pneumonia and need for MV (Table 2).

### Table 1: Inflammatory markers and thyroid function tests in healthy controls and in patients with COVID-19 and non-COVID-19 pneumonia, measured within 24 h of admission.

<table>
<thead>
<tr>
<th>Parameters at admission (normal range)</th>
<th>Healthy controls (n=19)</th>
<th>Community-acquired non-COVID-19 pneumonia (n=19)</th>
<th>COVID-19 pneumonia (n=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender M/F</td>
<td>9M/10F</td>
<td>9M/10F</td>
<td>11M/11F</td>
</tr>
<tr>
<td>Age, years</td>
<td>59(55–64)</td>
<td>63(55–67)</td>
<td>63(55–67)</td>
</tr>
<tr>
<td>CRP (&lt;5 mg/L)</td>
<td>2.0(1.0–3.0)</td>
<td>79.0(29.6–158.0)***</td>
<td>48.4(28.4–145.1)***</td>
</tr>
<tr>
<td>Ferritin (16, 323 µg/L)</td>
<td>69(46–95)</td>
<td>243(170–1,627)***</td>
<td>328(181–1,574)***</td>
</tr>
<tr>
<td>D-dimers (≤2.74 nmol/L)</td>
<td>0.00(0.0–0.55)</td>
<td>7.23(0.4–21.52)***</td>
<td>9.25(6.60–15.0)***</td>
</tr>
<tr>
<td>T3 (1.23, 3.08 nmol/L)</td>
<td>1.66 ± 0.23</td>
<td>1.17 ± 0.23***</td>
<td>1.40 ± 0.45†</td>
</tr>
<tr>
<td>FT3 (3.1, 6.8 pmol/L)</td>
<td>4.78 ± 0.54</td>
<td>3.48 ± 0.88***</td>
<td>3.57 ± 0.97***</td>
</tr>
<tr>
<td>T4 (65.64, 181.48 nmol/L)</td>
<td>102.84 ± 14.42</td>
<td>98.85 ± 16.09</td>
<td>111.08 ± 28.70</td>
</tr>
<tr>
<td>FT4 (11.97, 21.88 pmol/L)</td>
<td>14.42 ± 1.80</td>
<td>16.86 ± 3.22†</td>
<td>18.66 ± 4.38†</td>
</tr>
<tr>
<td>TSH (0.27, 4.20 mIU/L)</td>
<td>1.51(1.25–2.44)</td>
<td>1.12(0.80–1.59)†</td>
<td>1.04(0.39–1.79)†</td>
</tr>
<tr>
<td>rT3 (0.11, 0.40 nmol/L)</td>
<td>0.37 ± 0.08</td>
<td>0.41 ± 0.09†</td>
<td>0.41 ± 0.06†</td>
</tr>
<tr>
<td>Ab-TPO (&gt;34 IU/ml)</td>
<td>10.10(9.10–12.20)</td>
<td>20.60(13.10–28.00)***</td>
<td>18.30(12.95–34.70)***</td>
</tr>
</tbody>
</table>

M, males; F, females; IU, international units. Data are presented as mean ± SD (normally distributed) and as median (IQR) (non-normally distributed). *p<0.05 vs. healthy controls, **p<0.01 vs. healthy controls, ***p<0.001 vs. healthy controls.
patients compared to healthy controls, a finding typical of NTIS [12, 13].

In NTIS, serum T3 typically drops rapidly within 1 h of the onset of illness and the magnitude of its drop is proportional to disease severity, whereas rT3 increases a few hours later [13]. If the illness is severe or prolonged enough, T4 and TSH also decrease, and a type of transient acquired central hypothyroidism occurs [12]. 31.8% of our COVID-19 patients had subnormal TSH but normal or even high-normal T4 and FT4. We suggest that this common [1–4, 6] pattern in TFT, which could falsely lead to the diagnosis of subclinical thyrotoxicosis, is probably a unique presentation of NTIS in COVID-19. The isolated subnormal serum TSH could be explained by the excessive release of proinflammatory cytokines characterizing COVID-19, as cytokines decrease TRH and TSH secretion [14]. Another potential mechanism might be a direct suppressing effect of SARS-CoV-2 to the hypothalamus and/or pituitary, which has been shown for SARS-CoV-1 [15, 16].

Besides, glucocorticoids which are commonly used in COVID patients also suppress TSH. Notably, none of our patients received dexamethasone before blood sampling.

The only thyroid parameter with a prognostic significance in our study was Ab-TPO. Ab-TPO were higher in patients with COVID-19 progressing to SRF and were positively correlated with ferritin, a marker with established prognostic role [17]. Furthermore, Ab-TPO positivity was associated with severe COVID-19 pneumonia and with progression to SRF. The presence of increased autoantibodies other than Ab-TPO has been reported in up to 45% of COVID-19 patients, and it has been correlated with adverse prognosis [18]. Although the pre-COVID-19 Ab-TPO levels of our patients are unknown, none of them had known rheumatologic/autoimmune diseases and, therefore, it seems that SARS-CoV-2 might trigger thyroid autoimmunity in the context of a generalized immune response, as recently shown [19]. In this framework, Ab-TPO positivity could identify COVID-19 patients with exaggerated immune system activation, being at increased risk of severe/complicated illness. Still, the possibility of SARS-CoV-2-induced direct thyroid damage cannot be completely excluded, as destructive thyroiditis could lead to a transient anti-thyroid antibody rise and might also worsen the clinical course of COVID-19 patients. Unfortunately, data regarding longitudinal evolution of Ab-TPO levels in our patients are not available to support this hypothesis.

Our study is limited by the relatively small number of participants and the lack of follow-up of the thyroid function parameters in our patients; thus, more studies are needed in order to confirm our data.

Table 2: Comparisons of inflammatory markers and thyroid function tests measured within 24 h of admission, in patients with COVID-19 pneumonia according to disease severity on admission, and according to development of severe respiratory failure requiring mechanical ventilation (MV). Data are presented as mean ± SD (normally distributed) and as median (IQR) (non-normally distributed).

<table>
<thead>
<tr>
<th>Parameters at admission (normal range)</th>
<th>COVID-19 pneumonia non-severe (n=13)</th>
<th>COVID-19 pneumonia severe (n=9)</th>
<th>p-Value</th>
<th>No need for MV (n=15)</th>
<th>Need for MV (n=7)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M/F)</td>
<td>4M/9F</td>
<td>7M/2F</td>
<td>0.030</td>
<td>5M/10F</td>
<td>6M/1F</td>
<td>0.022</td>
</tr>
<tr>
<td>Age, years</td>
<td>64(56–67)</td>
<td>62(47–72)</td>
<td>NS</td>
<td>66(56–68)</td>
<td>62(47–76)</td>
<td>NS</td>
</tr>
<tr>
<td>CRP (&lt;5 mg/L)</td>
<td>31.7(21.6–53.0)</td>
<td>128.0(59.0–209.5)</td>
<td>0.012</td>
<td>37.8</td>
<td>106.8</td>
<td>NS</td>
</tr>
<tr>
<td>Ferritin (16, 323 μg/L)</td>
<td>186(138–252)</td>
<td>1,416(403–2,277)</td>
<td>0.006</td>
<td>224(169–381)</td>
<td>1988</td>
<td>0.003</td>
</tr>
<tr>
<td>D-dimer (&lt;2.74 nmol/L)</td>
<td>8.21(4.55–13.03)</td>
<td>14.02(5.80–30.88)</td>
<td>NS</td>
<td>7.83</td>
<td>14.13</td>
<td>NS</td>
</tr>
<tr>
<td>rT3 (1.23, 3.08 nmol/L)</td>
<td>1.48 ± 0.31</td>
<td>1.31 ± 0.62</td>
<td>NS</td>
<td>1.48 ± 0.39</td>
<td>1.25 ± 0.62</td>
<td>NS</td>
</tr>
<tr>
<td>FT3 (3.1, 6.8 pmol/L)</td>
<td>3.75 ± 0.69</td>
<td>3.30 ± 1.28</td>
<td>NS</td>
<td>3.69 ± 0.79</td>
<td>3.28 ± 1.43</td>
<td>NS</td>
</tr>
<tr>
<td>T4 (65.64, 181.48 nmol/L)</td>
<td>117.90 ± 25.87</td>
<td>101.17 ± 31.15</td>
<td>NS</td>
<td>114.68 ± 26.00</td>
<td>99.24 ± 36.04</td>
<td>NS</td>
</tr>
<tr>
<td>T4 (11.97, 21.88 pmol/L)</td>
<td>18.92 ± 3.48</td>
<td>18.28 ± 5.41</td>
<td>NS</td>
<td>18.66 ± 3.35</td>
<td>18.53 ± 6.69</td>
<td>NS</td>
</tr>
<tr>
<td>TSH (0.27, 4.20 μIU/L)</td>
<td>0.87(0.45–1.57)</td>
<td>1.37(0.07–2.20)</td>
<td>NS</td>
<td>1.01</td>
<td>1.54</td>
<td>NS</td>
</tr>
<tr>
<td>rT3 (0.11, 0.40 nmol/L)</td>
<td>0.41 ± 0.06</td>
<td>0.40 ± 0.08</td>
<td>NS</td>
<td>0.41 ± 0.06</td>
<td>0.41 ± 0.08</td>
<td>NS</td>
</tr>
<tr>
<td>Ab-TPO (&lt;34 IU/ml)</td>
<td>17.45(11.90–22.45)</td>
<td>31.80(13.85–61.20)</td>
<td>NS</td>
<td>16.90</td>
<td>46.87</td>
<td>0.029</td>
</tr>
<tr>
<td>Ab-TPO positive</td>
<td>7.7%</td>
<td>44.4%</td>
<td>0.038</td>
<td>13.3%</td>
<td>50%</td>
<td>0.013</td>
</tr>
</tbody>
</table>

M, males; F, females; IU, international units; NS, not significant; p-values in bold are those below the set level of significance.
In conclusion, we have shown that alterations in TFT in glucocorticoid-naive patients with COVID-19 pneumonia are more consistent with NTIS than with thyrotoxicosis. The frequently observed pattern of subnormal TSH, low-normal T3/FT3, normal T4, and high-normal FT4 might represent a unique type of NTIS, manifesting during the acute phase of COVID-19 pneumonia. Finally, positive Ab-TPO might be a potential adverse prognostic factor.

**Research funding:** None declared.

**Author contributions:** Stelios F. Assimakopoulos: conceptualization, writing and critically revising the manuscript. Georgios K. Markantes: statistical analysis, writing the manuscript. Dimitris Papageorgiou: data collection. Irene Mamali: hormonal measurements. Kostas B. Markou: conceptualization, writing and critically revising the manuscript. Markos Marangos: conceptualization, writing and critically revising the manuscript. Marina A. Michalaki: conceptualization, writing and critically revising the manuscript.

**Competing interests:** Authors state no conflict of interest.

**Informed consent:** Informed consent was obtained from all individuals included in this study.

**Ethical approval:** Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the authors’ Institutional Review Board (University Hospital of Patras Ethics Committee, 9632/17-05-2016).

**References**


**Supplementary Material:** The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-0511).